{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-22-000097","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.366868+00:00","generated_at":"2026-06-24T05:45:50.989774+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged","bullets":["Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).","Gross margin 75.1% vs 75.8% prior; operating loss $13.7M vs $15.1M prior.","Net loss per share $0.32 (adjusted $0.32) vs $0.36 GAAP and $0.30 adjusted prior year.","Adjusted EBITDA loss $3.2M vs $2.7M prior; FY 2022 revenue guide $323M-$333M (18-21% growth).","Growth driven by cryoSPHERE, AtriClip, ENCOMPASS, and EPi-Sense products."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-22-000097","json":"https://secwatch.observer/filing/0001323885-22-000097.json","markdown":"https://secwatch.observer/filing/0001323885-22-000097.md","text":"https://secwatch.observer/filing/0001323885-22-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/0001323885-22-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/atrc-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:45:50.989774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}